文献速递炎症性肠病

乌帕替尼在诱导治疗第一周内减轻克罗恩病症状

Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-03-15

该事后分析汇总两项3期诱导试验(U-EXCEL、U-EXCEED)和一项维持试验(U-ENDURE)数据,比较乌帕替尼45 mg每日一次与安慰剂治疗克罗恩病前15天的症状改善。乌帕替尼45 mg在治疗第5或6天即快速缓解症状,第2周起症状评分改善显著优于安慰剂并维持至第12周。

要点

  • 乌帕替尼45 mg每日一次在治疗第5或6天即快速缓解克罗恩病症状。
  • 第2周起乌帕替尼45 mg症状评分改善显著优于安慰剂并维持至第12周。
  • 乌帕替尼45 mg组SF/APS临床缓解率为21.1%,安慰剂组为8.9%。

核心结论

  • 乌帕替尼45 mg每日一次在克罗恩病诱导治疗第一周内即快速缓解临床症状。

研究设计与样本

  • 事后分析,汇总2项3期多中心双盲12周诱导试验(U-EXCEL和U-EXCEED)和1项维持试验(U-ENDURE)数据,共分析1021例患者(乌帕替尼45 mg组674例,安慰剂组347例)。

主要发现

  • 乌帕替尼45 mg组在粪便频率<3次/日和腹痛评分≤1分方面疗效优于安慰剂,第5或6天即快速缓解,无论既往是否暴露于生物制剂。
  • 乌帕替尼45 mg组粪便频率和腹痛评分的平均变化从第2周起大于安慰剂(分别为-2.0和-0.5,P < .001),并维持至第12周(分别为-3.0和-1.0,P < .001)。
  • 乌帕替尼45 mg组首次达到每日SF/APS临床缓解的时间早于安慰剂(中位13天 vs 中位32天)。
  • 从第2周起,乌帕替尼45 mg组SF/APS临床缓解率(21.1% vs 8.9%)和临床反应率(58.8% vs 37.9%)均优于安慰剂(两者P ≤ .01)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Upadacitinib (UPA), an oral Janus kinase inhibitor, is approved to treat moderately to severely active Crohn's disease (CD). Because symptomatic response is an important initial treatment goal for patients, we evaluated the rapidity of symptomatic improvement in patients with CD receiving UPA 45 mg once daily (UPA45) induction therapy. METHODS: This post hoc analysis included pooled data from 2 phase 3, multicenter, double-blind, 12-week induction trials (U-EXCEL and U-EXCEED) and 1 maintenance trial (U-ENDURE). Daily diary data for the first 15 days of UPA45 or placebo (PBO) treatment were used to analyze improvement in very soft/liquid stool frequency (SF) and abdominal pain score (APS). Clinical outcomes were evaluated at every study visit. RESULTS: Overall, 1021 patients (n = 674 UPA45; n = 347 PBO) were analyzed. UPA45 demonstrated greater efficacy vs PBO for SF <3 and APS ≤1, providing rapid relief by day 5 or 6, regardless of prior biologic exposure. Mean changes in SF and APS were greater with UPA45 beginning at week 2 (-2.0 and -0.5, respectively; P < .001) and were maintained through week 12 (-3.0 and -1.0, respectively; P < .001) vs PBO. The first achievement of daily SF/APS clinical remission occurred earlier with UPA45 (median, 13 d) vs PBO (median, 32 d), and patients treated with UPA45 showed improved rates of SF/APS clinical remission (21.1% UPA45 vs 8.9% PBO) and clinical response (58.8% UPA45 vs 37.9% PBO) starting at week 2 (both P ≤ .01). CONCLUSIONS: UPA45 provided rapid relief of clinical symptoms within the first week of treatment in patients with CD. CLINICALTRIALS: gov numbers: NCT03345849, NCT03345836, and NCT03345823.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Colombel JF, Hisamatsu T, Atreya R, et al. Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy. Clin Gastroenterol Hepatol. 2024. PMID: 38492903. doi:10.1016/j.cgh.2024.02.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。